Increased G3BP2-Tau interaction in tauopathies is a natural defense against Tau aggregation.


Journal

Neuron
ISSN: 1097-4199
Titre abrégé: Neuron
Pays: United States
ID NLM: 8809320

Informations de publication

Date de publication:
06 09 2023
Historique:
received: 16 08 2022
revised: 21 02 2023
accepted: 31 05 2023
medline: 11 9 2023
pubmed: 30 6 2023
entrez: 29 6 2023
Statut: ppublish

Résumé

Many RNA-binding proteins (RBPs), particularly those associated with RNA granules, promote pathological protein aggregation in neurodegenerative diseases. Here, we demonstrate that G3BP2, a core component of stress granules, directly interacts with Tau and inhibits Tau aggregation. In the human brain, the interaction of G3BP2 and Tau is dramatically increased in multiple tauopathies, and it is independent of neurofibrillary tangle (NFT) formation in Alzheimer's disease (AD). Surprisingly, Tau pathology is significantly elevated upon loss of G3BP2 in human neurons and brain organoids. Moreover, we found that G3BP2 masks the microtubule-binding region (MTBR) of Tau, thereby inhibiting Tau aggregation. Our study defines a novel role for RBPs as a line of defense against Tau aggregation in tauopathies.

Identifiants

pubmed: 37385246
pii: S0896-6273(23)00434-8
doi: 10.1016/j.neuron.2023.05.033
pii:
doi:

Substances chimiques

tau Proteins 0
RNA-Binding Proteins 0
G3BP2 protein, human 0
Adaptor Proteins, Signal Transducing 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2660-2674.e9

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests C.W., M.T., N.J.P., T.D., M.E., S.T., L.F., A.B., R.J., and F.G. are employed by F. Hoffmann-La Roche. Parts of the work in this study have been filed in the patent PCT/EP2023/056281.

Auteurs

Congwei Wang (C)

Roche Pharma Research and Early Development, Roche Innovation Center Basel, 4070 Basel, Switzerland. Electronic address: congwei.wang@roche.com.

Marco Terrigno (M)

Roche Pharma Research and Early Development, Roche Innovation Center Basel, 4070 Basel, Switzerland.

Juan Li (J)

School of Life Sciences, University of Science and Technology of China, 230026 Anhui, China.

Tania Distler (T)

Roche Pharma Research and Early Development, Roche Innovation Center Basel, 4070 Basel, Switzerland.

Nikhil J Pandya (NJ)

Roche Pharma Research and Early Development, Roche Innovation Center Basel, 4070 Basel, Switzerland.

Martin Ebeling (M)

Roche Pharma Research and Early Development, Roche Innovation Center Basel, 4070 Basel, Switzerland.

Stefka Tyanova (S)

Roche Pharma Research and Early Development, Roche Innovation Center Basel, 4070 Basel, Switzerland.

Jeroen J M Hoozemans (JJM)

Department of Pathology, Amsterdam Neuroscience, Amsterdam University Medical Centers, 1081 HV Amsterdam, the Netherlands.

Anke A Dijkstra (AA)

Department of Pathology, Amsterdam Neuroscience, Amsterdam University Medical Centers, 1081 HV Amsterdam, the Netherlands.

Luisa Fuchs (L)

Roche Pharma Research and Early Development, Roche Innovation Center Basel, 4070 Basel, Switzerland.

Shengqi Xiang (S)

School of Life Sciences, University of Science and Technology of China, 230026 Anhui, China.

Azad Bonni (A)

Roche Pharma Research and Early Development, Roche Innovation Center Basel, 4070 Basel, Switzerland.

Fiona Grüninger (F)

Roche Pharma Research and Early Development, Roche Innovation Center Basel, 4070 Basel, Switzerland.

Ravi Jagasia (R)

Roche Pharma Research and Early Development, Roche Innovation Center Basel, 4070 Basel, Switzerland. Electronic address: ravi.jagasia@roche.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH